pangchingwen
2021-11-30
good
NRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals股价早盘飙升27%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609043775,"tweetId":"609043775","gmtCreate":1638227700949,"gmtModify":1638227702516,"author":{"id":3581818742728168,"idStr":"3581818742728168","authorId":3581818742728168,"authorIdStr":"3581818742728168","name":"pangchingwen","avatar":"https://static.tigerbbs.com/31b0269cbebdce24b628856129a8ab15","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":71,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>good</p></body></html>","htmlText":"<html><head></head><body><p>good</p></body></html>","text":"good","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609043775","repostId":1137204965,"repostType":4,"repost":{"id":"1137204965","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638199520,"share":"https://www.laohu8.com/m/news/1137204965?lang=zh_CN&edition=full","pubTime":"2021-11-29 23:25","market":"us","language":"en","title":"NRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals股价早盘飙升27%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137204965","media":"Tiger Newspress","summary":"NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher lik","content":"<p>NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.</p><p><blockquote>NRx Pharmaceuticals发现ZYESAMI从严重的COVID-19中生存和恢复的可能性显着增加，股价在早盘交易中飙升27%®（阿维他地尔）治疗的患者既往接受过瑞德西韦治疗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/50a474a64f50c3ff0cfc1f4f77930314\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.</p><p><blockquote>NRx Pharmaceuticals今天宣布，它已经完成了一项分析，以确定表明ZYESAMI治疗后有实质性改善的临床证据®（阿维他地尔）在危重新冠肺炎和呼吸衰竭患者中优于瑞德西韦等现有疗法。NRx请David Schoenfeld教授进行分析，他是世界上发表文章最广泛的统计学家之一，在危及生命的肺部疾病方面拥有独特的专业知识。</blockquote></p><p> <ul> <li>Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population</p><p><blockquote><ul><li>在COVID-AIV试验中之前接受过瑞德西韦治疗的ZYESAMI和安慰剂治疗患者亚组中进行了分析，约占研究人群的70%</li></ul></blockquote></p><p></li> <li>Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir</p><p><blockquote><li>应美国食品药品监督管理局（FDA）的要求，进行了分析，要求提供ZYESAMI与目前批准的治疗（包括瑞德西韦）相比的效果的额外临床数据</li></blockquote></p><p></li> <li>NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests</p><p><blockquote><li>NRx将向FDA提交新的分析和安全性数据，以支持紧急使用授权和突破性疗法认定请求</li></blockquote></p><p></li> <li>US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients</p><p><blockquote><li>美国国立卫生研究院赞助的比较ZYESAMI和remdesivir单独和联合使用效果的试验继续招募患者</li></blockquote></p><p></li> </ul> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals股价早盘飙升27%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals股价早盘飙升27%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 23:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.</p><p><blockquote>NRx Pharmaceuticals发现ZYESAMI从严重的COVID-19中生存和恢复的可能性显着增加，股价在早盘交易中飙升27%®（阿维他地尔）治疗的患者既往接受过瑞德西韦治疗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/50a474a64f50c3ff0cfc1f4f77930314\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.</p><p><blockquote>NRx Pharmaceuticals今天宣布，它已经完成了一项分析，以确定表明ZYESAMI治疗后有实质性改善的临床证据®（阿维他地尔）在危重新冠肺炎和呼吸衰竭患者中优于瑞德西韦等现有疗法。NRx请David Schoenfeld教授进行分析，他是世界上发表文章最广泛的统计学家之一，在危及生命的肺部疾病方面拥有独特的专业知识。</blockquote></p><p> <ul> <li>Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population</p><p><blockquote><ul><li>在COVID-AIV试验中之前接受过瑞德西韦治疗的ZYESAMI和安慰剂治疗患者亚组中进行了分析，约占研究人群的70%</li></ul></blockquote></p><p></li> <li>Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir</p><p><blockquote><li>应美国食品药品监督管理局（FDA）的要求，进行了分析，要求提供ZYESAMI与目前批准的治疗（包括瑞德西韦）相比的效果的额外临床数据</li></blockquote></p><p></li> <li>NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests</p><p><blockquote><li>NRx将向FDA提交新的分析和安全性数据，以支持紧急使用授权和突破性疗法认定请求</li></blockquote></p><p></li> <li>US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients</p><p><blockquote><li>美国国立卫生研究院赞助的比较ZYESAMI和remdesivir单独和联合使用效果的试验继续招募患者</li></blockquote></p><p></li> </ul> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137204965","content_text":"NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.\n\nNRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.\n\nAnalysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population\nAnalysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir\nNRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests\nUS National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients","news_type":1,"symbols_score_info":{"NRXP":0.9}},"isVote":1,"tweetType":1,"viewCount":1005,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609043775"}
精彩评论